about
De-novo humoral immune responses to cancer-associated autoantigens during transition from chronic liver disease to hepatocellular carcinoma.Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes.A high throughput method for identifying personalized tumor-associated antigensCell-based vaccines for the stimulation of immunity to metastatic cancers.Immunotherapy of radioresistant mammary tumors with early metastasis using molecular chaperone vaccines combined with ionizing radiation.Aberrant expression of homeobox gene HOXA7 is associated with müllerian-like differentiation of epithelial ovarian tumors and the generation of a specific autologous antibody response.MGEA6 is tumor-specific overexpressed and frequently recognized by patient-serum antibodies.A novel tumour associated leucine zipper protein targeting to sites of gene transcription and splicing.Dendritic cells and immunotherapy for malignant disease.Progress on new vaccine strategies for the immunotherapy and prevention of cancer.Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer.Vaccines in oncology: background and clinical potential.Cancer genetics and tumor antigens: time for a combined view?Promotion of tumor invasion by cooperation of granulocytes and macrophages activated by anti-tumor antibodies.A serologically identified tumor antigen encoded by a homeobox gene promotes growth of ovarian epithelial cells.The identification of auto-antibodies in pancreatic cancer patient sera using a naturally fractionated Panc-1 cell line.Immunotherapy of cancer by active vaccination: does allogeneic bone marrow transplantation after non-myeloablative conditioning provide a new option?Antigen-specific immunotherapy and cancer vaccines.Heat shock proteins and cancer vaccines: developments in the past decade and chaperoning in the decade to comeInterleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice.Tumor-associated antigen arrays for the serological diagnosis of cancer.Serum autoantibodies as biomarkers for early cancer detection.Peptide vaccines for hematological malignancies: a missed promise?A highly sensitive and selective aptasensor based on graphene oxide fluorescence resonance energy transfer for the rapid determination of oncoprotein PDGF-BB.Translation initiation factor eIF-4G is immunogenic, overexpressed, and amplified in patients with squamous cell lung carcinoma.Induction of ErbB-2/neu-specific protective and therapeutic antitumor immunity using genetically modified dendritic cells: enhanced efficacy by cotransduction of gene encoding IL-12.Cytotoxic T-lymphocyte clones, established by stimulation with the HLA-A2 binding p5365-73 wild type peptide loaded on dendritic cells In vitro, specifically recognize and lyse HLA-A2 tumour cells overexpressing the p53 protein.Generation and characterization of gp100 peptide-specific NK-T cell clones.Therapy with cultured T cells: principles revisited.Listeria monocytogenes: a potent vaccine vector for neoplastic and infectious disease.Generation and phenotypic characterization of new human ovarian cancer cell lines with the identification of antigens potentially recognizable by HLA-restricted cytotoxic T cells.Design of enhanced agonists through the use of a new virtual screening method: application to peptides that bind class I major histocompatibility complex (MHC) molecules.Human cortactin as putative cancer antigen.Human HER-2/neu protein immunization circumvents tolerance to rat neu: a vaccine strategy for 'self' tumour antigens.B cells inhibit induction of T cell-dependent tumor immunity.Quantification of HER2 autoantibodies in the amplification phenomenon of HER2 in breast cancer.
P2860
Q31938591-E48BCA8C-8568-4A1F-99ED-37B71877E758Q32142930-583A5734-3AAD-4DC8-90E7-DAD82FC86039Q33658767-DF66C3B4-812A-4D66-9BF7-E30F2B585FF9Q33776134-00FD36B6-A6C9-4920-904E-9556F2E83E54Q33859251-92F17184-B312-40FB-BACE-9370A6924BBEQ33953046-7CC78197-38A6-4654-B8BB-218C68CB2942Q34110478-EA71721C-E80D-483A-A497-4941E314EBC4Q34130453-37D5426A-4D32-4D11-8458-20D8871CB7B9Q34216506-1731958E-F91F-4109-8AAE-52B9EFC6CA99Q34328457-65AB56D3-D470-4E9D-B2C0-DA5800EF2F42Q34353878-74F8008B-FF62-4D43-A7D2-4879BCC06813Q34439914-D3E3DD17-B827-458E-95BD-495F31BE047AQ34495646-CEF69852-64C9-46FB-A29D-B082A720FA23Q34786193-8490501B-FEEE-47AB-9DD4-E7A87D9AB3FDQ35053221-833B926C-12A2-426F-8A37-D47C8BE7361AQ35089751-9C8E2C48-7B9B-424C-94C6-F051A25306F4Q35142329-33739A97-2515-4EB4-9C1E-C07E46034088Q35199473-1374984B-2351-416B-91B1-7B48771F54D9Q35624884-7885D880-51F7-4969-A53D-88D55A228AE5Q36401520-7B608E31-78BB-4D61-BD03-F14CD3868335Q36491988-0ABA1D17-229A-4AB8-BADF-1F686E00E412Q37622471-7024D8CD-D8B2-481F-8B5A-015633F02698Q38176546-3CED4AAC-3BD5-46A1-9845-4EA90CDD566EQ38318095-018DD522-ADF5-4B6C-AC65-E21A7601DF57Q40687265-07F81239-CAE7-4980-BBE0-85BA02AC118BQ40811138-492B1A60-1425-4F76-897B-67CC42A4B63EQ40903376-FB7CB0AE-A320-47D5-8284-9C72D0852567Q41060717-7B8A11E9-4787-4867-A510-FA73F27B7C77Q41561740-CF00644A-229A-47D7-A5C4-361514C89293Q41603483-0F623FFE-B9CA-463E-AA0C-ADC8358793C6Q42816165-BCD42E31-0747-4A30-863C-9E0BC77A54F8Q43093883-15D3D6C3-263D-48F6-A454-84DFF2E0DC0AQ47816653-955E8B29-9BE8-4CDE-B16A-75A65603F649Q48003979-1D418B26-6B76-4B46-84D0-BA0F1C6D46B4Q53682449-4CE1A8B7-CBB2-4227-BC85-7F91F32691CAQ54613090-356A1B3B-7883-486F-AC54-47251C29794E
P2860
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Oncogenic proteins as tumor antigens.
@en
type
label
Oncogenic proteins as tumor antigens.
@en
prefLabel
Oncogenic proteins as tumor antigens.
@en
P1476
Oncogenic proteins as tumor antigens.
@en
P2093
P304
P356
10.1016/S0952-7915(96)80079-3
P577
1996-10-01T00:00:00Z